Reolysin was developed from pre-clinical research done at the University of Calgary[REF][REF] Matt Coffey and Jim Strong led this research, and as Oncolytics' Chief Operating Officer, Coffey continues to play a pivotal role in the product's development.
Reolysin is a proprietary formulation of human reovirus, which is naturally found in mammalian respiratory and bowel systems [REF].